A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

Criteria the registry did not label

• The main inclusion criteria include but are not limited to:
• Adult participants must be age 18 or older
• Pediatric participants must be at least 2 years old and less than 18 years old.
• Diagnosis of precursor B-cell acute lymphoblastic leukemia (B-ALL) and have more than 5% blasts in the bone marrow by morphological assessment
• Participants with Ph-negative B-ALL with any of the following refractory/relapse criteria:
  • Failure to achieve complete remission after initial induction therapy;
  • Failure to achieve complete remission after salvage treatment;
  • Relapse with first remission duration ≤12 months
  • Second or later relapse
  • Relapse after allogeneic HSCT
• Participants with Ph-positive B-ALL who have received 2 (or more) tyrosine kinase inhibitors (TKIs) and meet the refractory/relapse criteria above or, those with the T315I mutation
  • The main exclusion criteria include but are not limited to:
• History of Burkitt's leukemia.
• Received anti-CD19 therapy within 3 months prior to entering the study
• Received allogeneic HSCT within 12 weeks prior to entering the study
• Received prior treatment with chimeric antigen receptor T cell (CAR-T) within 3 months prior to entering the study
• History or presence of clinically relevant central nervous system (CNS) pathology
• Has CNS infiltration. Participants who had previous CNS infiltration, but it was controlled with intrathecal therapy are permitted to enroll.
• History of immunodeficiency, including history of any positive test result for human immunodeficiency virus (HIV) antibody.
• History of serious cardiovascular and cerebrovascular disease
• Has active autoimmune diseases that may relapse